371 related articles for article (PubMed ID: 31042420)
1. Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
Lenz HJ; Ou FS; Venook AP; Hochster HS; Niedzwiecki D; Goldberg RM; Mayer RJ; Bertagnolli MM; Blanke CD; Zemla T; Qu X; Wirapati P; Tejpar S; Innocenti F; Kabbarah O
J Clin Oncol; 2019 Aug; 37(22):1876-1885. PubMed ID: 31042420
[TBL] [Abstract][Full Text] [Related]
2. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V
Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905
[TBL] [Abstract][Full Text] [Related]
3. Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies.
Aderka D; Stintzing S; Heinemann V
Lancet Oncol; 2019 May; 20(5):e274-e283. PubMed ID: 31044725
[TBL] [Abstract][Full Text] [Related]
4.
Battaglin F; Ou FS; Qu X; Hochster HS; Niedzwiecki D; Goldberg RM; Mayer RJ; Ashouri K; Zemla TJ; Blanke CD; Venook AP; Kabbarah O; Lenz HJ; Innocenti F
J Clin Oncol; 2024 Jun; 42(16):1890-1902. PubMed ID: 38457761
[TBL] [Abstract][Full Text] [Related]
5. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
6. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
7. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
Snyder M; Bottiglieri S; Almhanna K
Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
[TBL] [Abstract][Full Text] [Related]
8. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
9. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
[TBL] [Abstract][Full Text] [Related]
10. Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
Stahler A; Heinemann V; Schuster V; Heinrich K; Kurreck A; Gießen-Jung C; Fischer von Weikersthal L; Kaiser F; Decker T; Held S; Graeven U; Schwaner I; Denzlinger C; Schenk M; Neumann J; Kirchner T; Jung A; Kumbrink J; Stintzing S; Modest DP
Eur J Cancer; 2021 Nov; 157():71-80. PubMed ID: 34507244
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A
Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112
[TBL] [Abstract][Full Text] [Related]
12. Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China.
Xu R; Wang W; Zhu B; Lin X; Ma D; Zhu L; Zhao Q; Nie Y; Cai X; Li Q; Fang W; Li H; Wang N; Chen Y; Peng C; Fang H; Shen L
BMC Cancer; 2020 Feb; 20(1):131. PubMed ID: 32070312
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.
Nakamoto Y; Noda M; Mikami R; Tokunaga Y; Okumoto T; Kawamura T; Fujiwara H; Doi S; Tomita N
Int J Clin Oncol; 2020 Jul; 25(7):1285-1290. PubMed ID: 32200481
[TBL] [Abstract][Full Text] [Related]
14. Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
Nixon AB; Sibley AB; Liu Y; Hatch AJ; Jiang C; Mulkey F; Starr MD; Brady JC; Niedzwiecki D; Venook AP; Baez-Diaz L; Lenz HJ; O'Neil BH; Innocenti F; Meyerhardt JA; O'Reilly EM; Owzar K; Hurwitz HI
Clin Cancer Res; 2022 Jul; 28(13):2779-2788. PubMed ID: 34965954
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
16. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Cremolini C; Milione M; Marmorino F; Morano F; Zucchelli G; Mennitto A; Prisciandaro M; Lonardi S; Pellegrinelli A; Rossini D; Bergamo F; Aprile G; Urbani L; Morelli L; Schirripa M; Cardellino GG; Fassan M; Fontanini G; de Braud F; Mazzaferro V; Falcone A; Pietrantonio F
Br J Cancer; 2018 Apr; 118(7):955-965. PubMed ID: 29531324
[TBL] [Abstract][Full Text] [Related]
17. Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Laurent-Puig P; Grisoni ML; Heinemann V; Liebaert F; Neureiter D; Jung A; Montestruc F; Gaston-Mathe Y; Thiébaut R; Stintzing S
Clin Cancer Res; 2019 Jan; 25(1):134-141. PubMed ID: 30108104
[TBL] [Abstract][Full Text] [Related]
18. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
19. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
Moretto R; Corallo S; Belfiore A; Rossini D; Boccaccino A; Lonardi S; Centonze G; Morano F; Germani MM; Loupakis F; Morelli L; Urbani L; Brich S; Marmorino F; Prisciandaro M; Aprile G; Fassan M; Cillo U; Cattaneo L; Fontanini G; De Braud F; Falcone A; Milione M; Pietrantonio F; Cremolini C
Eur J Cancer; 2020 Aug; 135():78-88. PubMed ID: 32554314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
